Hillsdale Investment Management Inc. acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,400 shares of the pharmaceutical company’s stock, valued at approximately $309,000.

Other large investors have also recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Vertex Pharmaceuticals by 0.8% in the 2nd quarter. BlackRock Inc. now owns 19,405,981 shares of the pharmaceutical company’s stock worth $2,500,849,000 after buying an additional 159,601 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Vertex Pharmaceuticals by 3.1% in the second quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock valued at $2,188,196,000 after acquiring an additional 504,982 shares in the last quarter. State Street Corp grew its holdings in shares of Vertex Pharmaceuticals by 2.0% in the first quarter. State Street Corp now owns 12,013,178 shares of the pharmaceutical company’s stock valued at $1,313,647,000 after acquiring an additional 239,017 shares in the last quarter. Clearbridge Investments LLC grew its holdings in shares of Vertex Pharmaceuticals by 1.2% in the first quarter. Clearbridge Investments LLC now owns 8,754,618 shares of the pharmaceutical company’s stock valued at $957,317,000 after acquiring an additional 105,260 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of Vertex Pharmaceuticals by 253.8% in the second quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock valued at $651,454,000 after acquiring an additional 3,626,368 shares in the last quarter. Hedge funds and other institutional investors own 92.85% of the company’s stock.

In other news, CEO Jeffrey M. Leiden sold 216,624 shares of the company’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $160.96, for a total value of $34,867,799.04. Following the completion of the transaction, the chief executive officer now owns 400,266 shares of the company’s stock, valued at $64,426,815.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO Jeffrey Chodakewitz sold 573 shares of the company’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $129.85, for a total value of $74,404.05. Following the completion of the transaction, the chief marketing officer now directly owns 123,084 shares of the company’s stock, valued at approximately $15,982,457.40. The disclosure for this sale can be found here. Insiders sold a total of 514,920 shares of company stock valued at $82,633,446 in the last ninety days. 1.80% of the stock is currently owned by insiders.

VRTX has been the subject of a number of research analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $126.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, June 9th. Leerink Swann reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, June 22nd. Needham & Company LLC raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $155.00 price objective on the stock in a research report on Friday, June 23rd. BidaskClub downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 28th. Finally, Zacks Investment Research upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a research note on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, twenty-three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $167.04.

Shares of Vertex Pharmaceuticals Incorporated (VRTX) opened at 152.04 on Monday. The company has a 50-day moving average of $154.59 and a 200-day moving average of $128.57. The stock has a market capitalization of $38.33 billion, a P/E ratio of 146.05 and a beta of 1.73. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The firm had revenue of $544.10 million for the quarter, compared to the consensus estimate of $489.95 million. During the same period last year, the firm earned $0.24 EPS. The company’s revenue was up 26.1% on a year-over-year basis. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.62 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/02/hillsdale-investment-management-inc-invests-309000-in-vertex-pharmaceuticals-incorporated-vrtx-stock.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.